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Distinct binding of T lymphocytes to ICAM-1, 
-2 or -3 upon activation of LFA-1*
LFA-1 (CDlla/CD18) mediates leukocyte adhesion by binding to one of its 
ligands; ICAM-1, ICAM-2  or ICAM-3. Here, we investigated whether stimuli 
known to induce adhesion to ICAM-1 were also capable of inducing LFA- 
1-mediated adhesion of T lymphocytes to ICAM-2 and -3 transfectants. We 
observed that phorbol 12-myristate 13-acetate, Mn2+, cross-linking of CD3 or 
activating antibodies against LFA-1 enhanced LFA-l-mediated T cell adhesion to 
ICAM-2 and -3, although to a lesser extent than to ICAM-1.These results indicate 
that, similar to what has been reported for adhesion to ICAM-1, activation of 
LFA-1 is also required for adhesion to ICAM-2 and -3. Furthermore, the results 
suggest that ICAM-1 is the major ligand for LFA-1 on activated T lymphocytes. 
Interestingly, we observed that in contrast to activating antibodies against CD18, 
activating antibodies against CD 11a were incapable of inducing adhesion of 
LFA-1 to all three ligands. The antibody MEM-83 stimulated binding to ICAM-1, 
while at the same time inhibiting the interaction of LFA-1 with ICAM-2 and -3. 
The antibody NKI-L’16 selectively induced adhesion to ICAM-1 and -2 , but not to 
ICAM-3. Our results suggest that different conformations of LFA-1 are required 
to support adhesion to ICAM-1, -2  or -3, and that ligands may bind on different 
sites of the LFA-1 molecule.
1  Introduction
LFA-1 (CDlla/CD18) is a cell adhesion molecule that is 
involved in a broad range of immunological processes [1 , 2 ]. 
LFA-1 belongs to the [32- (CD 18) family of integrins, which 
consist of an a-chain and a (5-chain which are non- 
covalently linked [3], Thus far three ligands for LFA-1 have 
been described: ICAM-1 [4], ICAM-2 [5] or ICAM-3 [6-9], 
which are all members of the Ig-superfamily and have 5, 2 
and 5 Ig-like domains, respectively [5-8,10-12]. ICAM-1 is 
expressed on many cell types including lymphocytes and 
certain epithelial cells. ICAM-1 is strongly up-regulated on 
endothelial cells by various inflammatory cytokines [13], 
and is, therefore, important for the migration of leukocytes 
through endothelial cell layers into inflamed tissue [14]. 
ICAM-2 is mainly expressed on vascular endothelium and 
some lymphoid cells. In contrast to ICAM-1, ICAM-2 is not 
induced by cytokines [5, 15, 16]. ICAM-2 is the predomi­
nant ligand for LFA-1 on resting endothelial cells, and has, 
therefore, been suggested to be important for recirculation 
of resting lymphocytes [15]. In contrast to ICAM-1 and -2,
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ICAM-3 is only expressed on leukocytes with the exception 
of some endothelial cells in tumors [17, 18]. Since ICAM-3 
is the most abundantly expressed ICAM on resting lympho­
cytes it has been proposed to be the major ligand for LFA-1 
during the initiation of immune responses. This hypothesis 
is supported by the finding that resting lymphocytes adhere 
to purified LFA-1 predominantly through ICAM-3 [9]. 
Recent reports suggest that ICAM-3 serves not only as an 
adhesion receptor, but is also involved in signal transduc­
tion [19,20]. ICAM-3 is a co-stimulatory molecule for both 
resting and activated T cells [19]. Furthermore, it was 
shown that cross-linking of ICAM-3 by anti-ICAM-3 mAb 
increases the avidity of LFA-1 for ICAM-1 [20].
Considerable information has been gathered about the 
regulation of LFA-1-mediated adhesion to ICAM-1. LFA-1 
does not mediate stable adhesion to ICAM-1 unless 
activated [21-23]. This activation can be induced by 
different stimuli and requires a physiological temperature, 
an intact cytoskeleton and the presence of divalent catioite 
[24]. Cross-linking of certain surface receptors on T lym­
phocytes, such as CD2 and CD3 [22, 23] or addition of the 
phorbol ester PM A [25, 26] generate intracellular signals 
that increase the avidity of LFA-1 for ICAM-1. In addition, 
divalent cations such as Mn2+ have been shown to stimulate 
LFA-l-mediated adhesion [27]. Enhanced LFA-l-me- 
diated binding to ICAM-1 is furthermore observed upon 
binding of certain unique activating antibodies directed 
against the LFA-1 a- or p-chain. Since Fab fragments of 
most of these antibodies induce adhesion, activation is not 
caused by cross-linking but is most likely due to the 
induction of a conformational change within the molecule 
[28-32]. Thus far, five LFA-1 activating antibodies have 
been described, which all bind to distinct epitopes 
(van Kooyk et al., submitted). NKI-L16 [28, 29] and 
MEM-83 [30] recognize epitopes on the LFA-1 a-chain 
(CDlla), while KIM127 [31], KIM185 [32] and MEM-48 
(van Kooyk et al., submitted) are directed against the 
common (52-chain (CD18).
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Since little is known about requirements for adhesion of 
LFA-1 to ICAM-2 and -3, we here investigated whether 
stimuli known to induce LFA-l-mediated adhesion to 
ICAM-1 were also capable of stimulating binding of 
T lymphocytes to ICAM-2 and -3,
2 Materials and methods
2.1 mAb and chemicals
The following mAb were used: NKI-L15 (IgG2A) [33], 
NKI-L16 (IgG2 A) [28,29] and MEM-83 (IgGl) [30] 
directed against the a-chain of LFA-1 (CD 11 a), MEM-48 
(IgGl) (van Kooyk et al., submitted), KIM127 (IgGl) [31] 
and KIM185 (IgGl) [32] reactive with the LFA-1 P-chain 
(CD 18); mAb CBR-IC2/2 (IgG2A) reactive with ICAM-2 
(CD 102) [15], mAb CBR-IC3/1 (IgGl) [9] and mAb 
CBR-IC3/2 (IgG2A) [8 ] reactive with ICAM-3 (CD50); 
mAb CLB-T3/4E (IgE) [34] reactive with CD3; RR1/1 
(IgGl) [25] and REK-'l (IgGl) reactive with ICAM-1. MAb 
REK-1 was obtained by immunizing BALB/c mice with a 
CTL clone. Subsequently hybridoma supernatants were 
screened for reactivity with ICAM-1 transfectants (CD54). 
All mAb were used at a concentration of 5-10 jig/ml. 
Reagents used were PMA (50 ng/ml; Sigma Chemical CoM 
St. Louis, MO) and MnCb (10 m M ; diluted in Hepes/NaCl 
buffer; Sigma).
*
2.2 Cells
The T cell clone JS136 [35] was cultured as described 
previously [29]. Mouse L cells expressing ICAM-1 under 
control of the CMVAD 169 immediate early promoter, were 
obtained as described [36]. L cells and L cell transfectants 
were cultured in Iscove’s medium with L-glutamine (Gibco) 
supplemented with 5% FCS.
2,3 Immunofluorescence
Cells were incubated (30 min, 4°C) in PBS containing 1% 
wt/vol. BSA (Sigma Chemical Co.) and 0.02% wt/vol. azide 
with appropriate dilutions of the different mAb, followed 
by incubation with FITC-labeled goat F(ab' )2  anti-mouse 
IgG antibody (GAM-FITC; Nordic, Tilburg, The Nether­
lands) for 30 min at 4 °C The relative fluorescence intensity 
was measured on a FACScan (Becton Dickinson, Mountain 
View, CA).
2.4 Generation of mouse L cell transfectants expressing 
human ICAM-2 or ICAM-3 cDNA
Human ICAM-2 and ICAM-3 cDNA in the pCDM8  vector 
were used as described previously [12]. The plasmid 
PGK-hyg containing a fragment conferring hygromycin 
resistance under control of a PGK promoter, was obtained 
from Dr. H. te Riele [37]. Mouse L cells were co­
transfected with PGK-hyg plasmid and pCDM8-ICAM-2 or 
pCDM8-ICAM-3 constructs, using calcium phosphate 
coprecipitation according manufacturers procedures (Cal­
cium phoshate transfection system; BRL Life Technologies, 
Inc., Gaithersburg, MD). L cells expressing high amounts
of human ICAM-2 or ICAM-3 were obtained following 
selection in medium containing 500 jig/ml hygromycin B 
(Calbiochem, San Diego, CA) and subsequent positive 
sorting on a FACS tar (Becton Dickinson).
2.5 Adhesion assay
Monolayers of L cells transfected with ICAM-1, -2 or -3 or 
non-transfected L cells were grown in 96-well tissue culture 
plates. In these wells Na251Cr0 4 -labeled T lymphocytes 
were incubated with PMA (50 ng/ml), Mn2+ (1 mM) or with 
blocking or activating antibodies (5-10 |xg/ml) during 
10  min at room temperature, cells were centrifuged at 
400 rpm for 1 min and were subsequently incubated at 37 °C 
during 30 min. Non-adherent cells were washed away with 
warm medium, adherent cells were lysed with 1% Triton X- 
100 and radioactivity was quantified. Results are expressed 
as the mean per cent of cells binding from triplicate 
wells.
3 Results
3.1 Distinct binding of T lymphocytes to ICAM-1, -2 or 
-3 transfectants upon activation of LFA-1
To investigate the regulation of T lymphocyte adhesion to 
ICAM-1, -2 and -3, we generated stable mouse Lcell 
transfectants expressing high levels of ICAM-1, *-2 or 
ICAM-3 (Fig. 1). ICAM-1, -2 or -3 expressed on these cells 
is functional, since the LFA-1 activating antibody KIM185 
(CD18) induced adhesion of theT cell clone JS136 to either 
one of these transfectants. The T cell clone JS136 was 
selected for experiments, because of its high expression of 
LFA-1 on the cell surface [29]. Adhesion was specific since 
it could be blocked by antibodies directed against LFA-1 or 
by antibodies directed against ICAM-1, -2 and -3, respec­
tively (Fig. 2).
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Figure L  Expression of ICAM -1, -2 and -3 on L cell transfectants. 
M ouse L ceils were transfected with human ICAM-1, -2 or -3 
cD N A  as described in Sect. 2.4. L cell transfectants and non- 
transfected L cells were stained with antibodies against ICAM-1 
(R EK -1), ICAM-2 (CBR-IC2/2) or ICAM-3 (CBR-IC3/2) and 
GAM -FITC second antibody.
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Figure 2 . Adhesion o f JS136 T cells to monolayers o f  L-ICAM-1, 
-2  or -3 transfectants is LFA-1/ICAM specific. The number of 
adherent T cells on monolayers of L-ICAM-1, -2 o r -3 transfectants 
was determined after 30 min incubation at 37 °C, in the presence of 
m edium  alone (□ )  or in the presence o f the LFA-1 activating 
antibody KIM185 (■ )  at 10 |xg/ml, with or without blocking 
antibodies against LFA-1 (NKI-L15), ICAM-1 (R R 1/1), ICAM -2 
(C B R -IC 2/2) or ICAM-3 (CBR-IC3/1 +  CBR-IC3/2) at 10 fig/ml. 
Results are expressed as the mean percent o f adherent cells from  
triplicate wells. Non-specific adhesion to non-transfected L cells, 
which was less than 5%, was subtracted from adhesion to 
L-ICAM -1, -2 and -3 transfectants. Data are representative o f  three 
experiments.
Next we determined whether various stimuli known to 
activate the LFA-l/ICAM-1 interaction were also capable 
of inducing LFA-l-mediated binding of the T cell clone 
JS136 to ICAM-2 or -3 transfectants (Fig. 3). We observed 
that Mn2+, PMA and cross-linking of CD3 increased 
adhesion of JS136 T cells to ICAM-2 and -3, however to a 
lesser extent than adhesion to ICAM-1. LFA-l-mediated 
adhesion of JS136 could also be induced by LFA-1 activat­
ing antibodies. Interestingly, we observed differences in the 
capacity of the various antibodies to induce adhesion to 
ICAM-1, -2  or -3. Activating antibodies directed against 
the LFA-1 (3-chain induced adhesion to all three ligands. 
KIM185 was most effective and strongly increased adhesion 
to ICAM-1 , -2 and -3, while KIM127 increased adhesion to 
ICAM-1 to a higher extent than adhesion to ICAM-2 and 
-3. MEM-48 strongly increased adhesion to ICAM-1 and to 
a lesser extent to ICAM-2, while only weak binding to
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Figure 3. Adhesion o f  JS136 T cells to L-ICAM -1, -2 and -3 
transfectants induced by various LFA-1 activating stimuli, JS136 
T cells were incubated on monolayers o f L-ICAM -1, -2 or -3 
transfectants as described in Fig. 2, in the presence o f  medium  
alone ( □ )  or in the presence of P M A  (50 ng/ml) or antibodies 
against CD3 (10 [xg/ml) (H ), activating antibodies against the  
LFA-1 a - or (3-chain (10 (E3), or M n2+ ( ■ )  (1 m M ). D ata are
representative o f six experiments.
ICAM-3 was observed. In contrast to the activating anti­
bodies against the LFA-1 (3-chain, activating antibodies 
directed against the a-chain were not capable of stimulating 
adhesion to all three ligands. NKI-L16 induced adhesion to 
ICAM-1 and -2 but not to ICAM-3, while MEM-83 
stimulated binding to only ICAM-1.
3.2 MEM-83 induces LFA-l-mediated T cell adhesion 
to ICAM-1, but inhibits binding to ICAM-2 and 
ICAM-3
In an attempt to explain the observation that MEM-83 only 
induced LFA-1 mediated T cell adhesion to ICAM-1, we 
investigated whether MEM-83 interfered with binding of 
LFA-1 to ICAM-2 and -3 (Fig. 4).Tb this end we combined 
stimuli that induced adhesion of JS136 T cells to all three 
ligands with the MEM-83 antibody We observed that 
LFA-1 mediated T cell adhesion to ICAM-2 induced by 
KIM185 was blocked to background levels by MEM-83, 
whereas adhesion induced by KIM127 or PMA was only
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Figure 4 . Inhibition of LFA-1 m ediated adhesion o f  JS136 T cells 
to L-ICAM -2 and -3 transfectants by the activating antibody 
MEM-83 (C D IIa ), The number o f adherent JSI36 T c e lls  on  
monolayers o f L-ICAM -1, -2 or -3 transfectants was determined as 
described in Fig. 2, in the presence o f m edium  alone ( □ ) ,  the  
activating antibodies KIM185 or KIM 127 (C D  18; '10 jig/ml), PM A  
(50 ng/mi) or in the presence o f a com bination o f th ese  stimuli with  
MEM-83 (10 ¿ig/ml) (■ ) .  Data are representative o f  three experi­
ments.
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Figure 5. LFA -l-m ediated adhesion of JS136 T cells to L-ICAM-3 
transfectants is not inhibited by NKI-L16.The number of adherent 
JS136 T cells on monolayers of L-ICAM-1, -2 or -3 transfectants 
was determ ined as described in Fig. 2, in the presence of medium 
alone (□ ) ,  the activating antibodies KIM185 or KIM127 (CD18; 
10 |ig/m l), PM A  (50 ng/ml) or in the presence o f a combination of 
these stimuli with NKI-L16 (10 |ig/ml) (■ ) . Data are representa­
tive o f three experiments.
4 Discussion
partially inhibited. In contrast, MEM-83 inhibited adhe­
sion to ICAM-3, irrespective of the stimulus used to induce 
adhesion. In contrast, induced adhesion to ICAM-1 trans­
fectants was unaffected by the MEM-83 antibody, indicat­
ing that binding of MEM-83 does not interfere with binding 
of KIM127 or KIM185 to LFA-1, since these mAh recog­
nize distinct epitopes on LFA-1 (van Kooyk et al., submit­
ted).
3.3 NKI-L16 stimulates LFA-l-mediated T cell adhesion 
to ICAM-1 and -2, but not to ICAM-3
Since NKI-L16, like MEM-83, did not induce LFA- 
l-mediated T cell adhesion to ICAM-3, we investigated 
whether NKI-L16 inhibited binding of LFA-1 to ICAM-3 
(Fig. 5). We observed that in contrast to MEM-83, adhesion 
induced by KIM185, KIM127 or PMA was unaffected by 
the NKI-L16 antibody. These results indicate that the 
inability of NKI-L16 to induce adhesion to ICAM-3 is not 
due to inhibition of the interaction of LFA-1 with ICAM- 
3.
Using stable transfectants expressing ICAM-1, -2 or -3 
cDNA we investigated the capacity of LFA-1 to bind to 
each of these ligands. The results show that (1) similar to 
what has been reported for ICAM-1, activation of LFA-1 is 
also required for adhesion to ICAM-2 and -3. (2 ) Activation 
of LFA-1 yields highT cell adhesion to ICAM-1, interme­
diate adhesion to ICAM-2, and low adhesion to ICAM-3, 
suggesting that ICAM-1 is the major ligand for LFA-1 on 
activated T lymphocytes. (3) Adhesion to ICAM-1 and 
ICAM-2 can be induced by activating antibodies directed 
against the LFA-1 a- or (3-chain, while binding to ICAM-3 is 
only induced by activating antibodies against the LFA-1 
[3-chain. (4) MEM-83 induces adhesion to only ICAM-1, 
since it blocks the interaction of LFA-1 with ICAM-2 and 
-3. (5) NKI-L16 induces adhesion to only ICAM-1 and -2 
and not to ICAM-3; however, it does not inhibit binding of 
LFA-1 to ICAM-3.
The results obtained with MEM-83 suggest that this 
antibody is able to enforce a conformational change on 
LFA-1 that enhances adhesion to ICAM-1, but renders 
LFA-1 inaccessible to ICAM-2 and ICAM-3 . This may 
imply that ICAM-1 binds to a site in the LFA-1 molecule 
which is distinct from the binding sites for ICAM-2 and -3.
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MEM-83 maps to the I domain, supporting the hypothesis 
that the I domain is involved in binding of LFA-1 to its 
ligands [38-41]. However, the observation that MEM-83 is 
unable to induce adhesion to ICAM-2 and -3, does not 
exclude that the I domain is involved in binding of LFA-1 to 
ICAM-2 or -3, since it is still possible that binding site for 
ICAM-2 and -3, when located in the I domain, are sterically 
hindered by MEM-83. Studies using purified I domain 
fragments will be required to elucidate whether the I do­
main is involved in binding of LFA-1 to ICAM-2 and -3. In 
contrast to MEM-83, the incapacity of NKI-L16 to induce 
adhesion to ICAM-3 was not due to inhibition of the 
interaction of LFA-1 with ICAM-3. These results, there­
fore, suggest that LFA-1 can acquire a conformation that 
selectively binds to ICAM-1 and -2, but not to ICAM-3. 
From these data it is tempting to speculate that binding of 
LFA-1 to its different ligands may involve exposition of 
ligand-specific binding sites or induction of ligand-specific 
conformational changes in LFA-1. This notion is supported 
by the observation that adhesion of pi-integrins to their 
different ligands may also involve distinct conformational 
changes in integrin molecules. The |31-integrin activating 
antibody TS2/16 (CD29) induced stronger adhesion of 
VLA-4 to fibronectin than to VCAM-1, under suboptimal 
conditions [42]. In addition the activating antibody TASC 
(CD29) inhibited adhesion of (31-integrins to vitronectin, 
while it promoted adhesion to laminin and collagen [43]. 
However, our results do not exclude the possibility that the 
incapacity of NKI-L16 and MEM-83 to induce adhesion to 
ICAM-3 and ICAM-2 and -3 respectively, may be due to 
differences in the glycosylation of ICAM-1, -2 and -3 
molecules. Interestingly, ICAM-2 and ICAM-3 have three 
and five possible N-linked glycosylation sites in the first 
Ig-like domain, respectively, whereas ICAM-1 lacks glyco­
sylation in its first domain [5-8,11]. N-linked glycosylation 
in the first Ig-like domain may interfere with binding of 
ICAM-2 and -3 to the conformations of LFA-1 induced by 
MEM-83 or NKI-L16.
In contrast to the activating antibodies directed against the 
LFA-1 (3-chain, PMA or cross-linking of CD3 only slightly 
increased adhesion to ICAM-3, suggesting that activation 
of LFA-1 through intracellular signals does not result in 
strong binding of activated T cells to ICAM-3. However, it 
should be noted that an ever increasing number of cell 
surface receptors expressed by T cells has been implicated 
in activation of LFA-1 [44-49]. It is, therefore, possible that 
adhesion of LFA-1 to ICAM-3 requires intracellular signals 
generated upon triggering of surface receptors distinct from 
CD3. In contrast to our results, Campanero et al. [20] 
observed high adhesion of T cells to ICAM-3 purified from 
neutrophils, upon stimulation with PMA, NKI-L16 or CD3 
cross-linking. A possible explanation for these different 
results might be that ICAM-3 transfected into murine 
fibroblasts is differently glycosylated than ICAM-3 on 
neutrophils, and therefore less effective in supporting 
adhesion of LFA-1. However, the observation that strong 
adhesion to ICAM-3 transfectants was induced by activat­
ing antibodies against CD18, argues against this possibility. 
Furthermore, immunoprecipitation of ICAM-3 from L- 
ICAM-3 transfectants revealed a 128-kDa protein (not 
shown), which is comparable to the size of ICAM-3 on 
lymphocytes (124 kDa). Since ICAM-3 on neutrophils is 
135 kDa in size [17], this indicates that ICAM-3 molecules 
on L-ICAM-3 transfectants do not differ largely in overall
glycosylation from ICAM-3 molecules on neutrophils. 
Finally, LFA-l-mediated adhesion to purified ICAM-3 
molecules may differ from adhesion to ICAM-3 transfec­
tants. It has been shown that LFA-1 expressed on leuko­
cytes requires activation to bind to ICAM-1, while purified 
LFA-1 molecules are constitutively active [9, 10, 21-23], 
suggesting that coating of the purified receptors induces a 
conformational change in LFA-1. Similarly, coated, puri­
fied ICAM-3 molecules may be more capable of supporting 
adhesion than ICAM-3 molecules imbedded in the cell 
membrane. Therefore, direct comparison of the different 
models is required to determine which model most closely 
represents physiological conditions.
Conformational changes in LFA-1 may determine the 
ligand specificity of LFA-1, however differential expression 
of ligands on different cell types is another mechanism to 
regulate LFA-l-mediated adhesion. ICAM-3 is the most 
abundantly expressed ligand on resting lymphocytes and 
has, therefore, been proposed to be an important ligand for 
LFA-1 during the initiation of immune responses. This 
hypothesis is supported by the finding that resting lympho­
cytes bind to purified LFA-1 predominantly through 
ICAM-3 [9], Purified LFA-1 molecules are constitutively 
active, supporting our finding that activation of LFA-1 is 
required for adhesion to ICAM-3. We showed that LFA-1 
on resting lymphocytes can hardly be activated to bind to 
ICAM-1 [50], ICAM-2 or -3 (unpublished observations). 
Therefore, these results imply that during the initiation of 
immune responses ICAM-3 on resting lymphocytes has to 
bind to LFA-1 on more activated cells. These cells might be 
antigen-presenting cells, but possibly also other cell types 
are involved. To get more insight into the role of LFA- 
l/ICAM-3 in the initiation of immune responses, identifi­
cation of these cells is, therefore, of major importance.
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